Systemic Thread · Healthcare Extraction
The Pipeline
McKesson. Cardinal Health. AmerisourceBergen. Three Fortune 500 companies distributed 75% of the 76 billion opioid pills that killed hundreds of thousands of Americans. They knew what was happening. They gutted the regulator's enforcement power. They paid $21 billion in settlements. No executive faced criminal charges.
Companion to the Sackler family dossier (the manufacturer) and the Pharma Industrial Complex thread.
Act I: The Pipeline
Three companies distributed 75% of the 76 billion opioid pills that flooded America between 2006 and 2012. You've never heard of them. That was part of the plan.
The Sackler family made OxyContin. Purdue Pharma marketed it as non-addictive. The FDA approved it on inadequate evidence. But someone had to move the pills from the factory to the pharmacy. Three companies handled 75% of that job:
- McKesson — #6 on the Fortune 500; the largest pharmaceutical distributor in the United States
- Cardinal Health — #14 on the Fortune 500
- AmerisourceBergen — #10 on the Fortune 500 (renamed "Cencora" in 2023)
Together, they are called the "Big Three." Between 2006 and 2012, the three companies — along with Walgreens, CVS, and Walmart — distributed 76 billion oxycodone and hydrocodone pills across the United States, according to the DEA's own internal database (ARCOS), which the government and the drug industry fought for years to keep secret.
The Washington Post and West Virginia's Charleston Gazette-Mail won a year-long legal battle to force the database's release in 2019. What it showed: a country deliberately, systematically flooded with pills. And the companies that flooded it knew exactly what they were doing.
Act II: Flood Country
McKesson shipped 5 million opioid pills to a single pharmacy in a West Virginia town of 400 people. Their own monitoring system flagged the orders as suspicious. They kept shipping.
Kermit, West Virginia. Population: 392. Between 2006 and 2008, McKesson shipped 5 million opioid pills — hydrocodone tablets — to a single pharmacy called Sav-Rite. That's roughly 12,500 pills per day, for a town that could barely fill a high school gymnasium.
A McKesson warehouse employee noticed in 2007 and flagged the orders as suspicious. McKesson reviewed the flagged account, reported to the DEA that the purchases were "reasonable," and continued shipping. The orders at Sav-Rite were 36 times the level McKesson's own internal drug monitoring program permitted.
Kermit was not an isolated case. It was a pattern:
- Williamson, WV (pop. 2,900): Two pharmacies received 21 million opioid pills over a decade. One distributor filed 105 suspicious order reports about a single pharmacy in one year — including orders of 12,500 and 16,000 pills in a single day for a town of 2,000 — then kept shipping more than a million pills per year to that same pharmacy for five more years.
- Mount Gay-Shamrock, WV (pop. 1,779): One pharmacy received 16.5 million hydrocodone and oxycodone pills between 2006 and 2016.
From 2006 to 2012, McKesson alone shipped 162.6 million hydrocodone and oxycodone pills into West Virginia — while filing zero suspicious order reports with the DEA during that entire period.
Act III: They Knew
Federal law required distributors to report suspicious orders and halt shipments. The Big Three's own systems flagged the orders. They filed the reports, called the orders reasonable, and kept the pills moving.
Under the Controlled Substances Act, drug distributors have a legal duty to identify suspicious orders — orders of unusual size, unusual frequency, or that deviate substantially from a normal pattern — and to halt shipments pending DEA review. This is not a gray area. It is the foundational obligation of anyone licensed to distribute controlled substances in the United States.
The Big Three built internal monitoring systems to identify exactly these orders. Those systems worked. At Sav-Rite pharmacy in Kermit, McKesson's system flagged the orders. At pharmacies in Williamson, distributors filed over a hundred suspicious order reports. The flags were flying. The reports were being written.
And then the pills kept moving.
This is the heart of the crime: the monitoring systems were designed to generate paperwork, not to stop shipments. File a report, call the orders "reasonable," keep the contract. The distributors' business model depended on volume. A suspicious order flag that actually halted a shipment cost money. A suspicious order flag that generated a DEA form and let the pills through cost nothing.
A former DEA official described the industry's posture to Congress: the distributors "turned a blind eye" because "they were making too much money." The McKesson employee who flagged Sav-Rite was overruled by management. The pills went out.
Act IV: They Bought the Regulator
In 2016, at the height of the opioid epidemic, the drug industry wrote a law that stripped the DEA of its most potent enforcement tool — and got Congress to pass it unanimously.
The DEA had a weapon the industry feared: the immediate suspension order, which could halt suspicious shipments without a prior hearing if there was "imminent danger to public health or safety." The Big Three's lobbyists spent years working to eliminate it.
In April 2016 — as overdose deaths were surging toward a record — Congress passed the Ensuring Patient Access and Effective Drug Enforcement Act. The bill was drafted by a drug industry lawyer and shepherded through the House by Rep. Tom Marino (R-PA), who received $92,500 in industry donations during the bill's two-year legislative run. DEA officials later told investigators the law made it "virtually impossible" to freeze suspicious shipments.
The revolving door was already turning: seven months after the bill became law, Marino's chief of staff left to lobby for the National Association of Chain Drug Stores — the trade group that had been his boss's point man on the legislation.
The bill passed by unanimous voice vote in both chambers. President Obama signed it. No senator objected publicly. The drug industry's lobbying spend during this period dwarfed the NRA's: pharmaceutical manufacturers and distributors spent more than $100 million annually on federal lobbying throughout the epidemic.
Trump later withdrew Marino's nomination as drug czar after the Washington Post/60 Minutes investigation exposed his role in passing the bill. The law remained on the books.
Act V: $21 Billion. Zero Charges.
The Big Three paid $21 billion to settle opioid claims. McKesson's CEO made $639 million during the epidemic years and forfeited $780,000 — less than 0.2% of his compensation.
In February 2022, McKesson, Cardinal Health, and AmerisourceBergen finalized a $21 billion national opioid settlement with all 50 states, Washington DC, and 5 US territories — the largest opioid industry settlement in American history, to be paid over 18 years.
- McKesson: $7.4 billion
- Cardinal Health: $6.1 billion
- AmerisourceBergen: $6 billion
No executive at any of the three was criminally charged.
John Hammergren was CEO of McKesson for 17 years, retiring in April 2019. During his tenure, he received $639 million in total compensation. After the opioid settlements, the McKesson board "docked" his pay — he forfeited $780,000. In the year of the docking, he still took home $15 million. His change-of-control golden parachute was set at $469 million.
The only distributor executives to face criminal charges were at Rochester Drug Co-Operative — a small New York regional distributor, not one of the Big Three. Former CEO Laurence Doud III and former Chief Compliance Officer William Pietruszewski were charged with drug trafficking and conspiracy in 2019. The company pleaded guilty. This was, prosecutors noted, the first prosecution of its kind in US history.
The Big Three's executives were never asked to give back their compensation. The companies themselves continued operating under the same licenses that enabled the epidemic. The $21 billion — spread over 18 years — amounts to roughly 0.5% of the companies' combined revenue during the epidemic years.
Act VI: The Body Count
806,000 Americans have died from opioid overdose since 1999. Today, 217 people die every day. The pipeline that carried the first wave of those deaths ran through three Fortune 500 companies.
From 1999 to 2023, approximately 806,000 Americans died from an opioid overdose, according to the CDC. On average, 217 people die every day. The epidemic runs in three waves: prescription opioids (the pipeline wave), heroin (when doctors cut off prescriptions), and synthetic fentanyl (which now dominates). The first wave — the prescription wave — is the one McKesson, Cardinal Health, and AmerisourceBergen built.
The structural argument is simple: a corporation that ships 5 million pills to a town of 400 people is not a passive logistics provider. It is an active participant in mass poisoning. The Controlled Substances Act made this explicit: distributors are the last line of defense against diversion. That was their legal role. They abandoned it because the volume was profitable.
The distributors did not manufacture addiction and they did not prescribe a single pill. But they ran the supply chain that made it possible for a small-town pharmacy to receive a million pills a year, for a single doctor to write thousands of prescriptions, for an epidemic to spread from Appalachia to suburban cul-de-sacs to urban emergency rooms across the country.
Three people who had decision-making authority over those shipments — the people who reviewed the suspicious order flags and called them "reasonable" and kept the trucks rolling — are free. They have their compensation. They have their golden parachutes. They have not been charged with anything.
The people who died from prescription opioids are dead. Their families received, on average, a share of an $18-year payout from companies that are still operating. That is what accountability looks like when the perpetrators are Fortune 500 companies.